PT1152762E - Utilizacao de desoxipeganina no tratamento da demencia de alzheimer - Google Patents

Utilizacao de desoxipeganina no tratamento da demencia de alzheimer

Info

Publication number
PT1152762E
PT1152762E PT00907513T PT00907513T PT1152762E PT 1152762 E PT1152762 E PT 1152762E PT 00907513 T PT00907513 T PT 00907513T PT 00907513 T PT00907513 T PT 00907513T PT 1152762 E PT1152762 E PT 1152762E
Authority
PT
Portugal
Prior art keywords
dementia
alzheimer
treatment
deoxygeganin
desoxypeganine
Prior art date
Application number
PT00907513T
Other languages
English (en)
Inventor
Hans-Rainer Hoffmann
Bodo Asmussen
Thomas Hille
Klaus Opitz
Original Assignee
Hf Arzneimittelforsch Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hf Arzneimittelforsch Gmbh filed Critical Hf Arzneimittelforsch Gmbh
Publication of PT1152762E publication Critical patent/PT1152762E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT00907513T 1999-02-19 2000-02-08 Utilizacao de desoxipeganina no tratamento da demencia de alzheimer PT1152762E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19906975A DE19906975B4 (de) 1999-02-19 1999-02-19 Arzneiform zur Behandlung von Alzheimer'scher Demenz

Publications (1)

Publication Number Publication Date
PT1152762E true PT1152762E (pt) 2005-08-31

Family

ID=7898022

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00907513T PT1152762E (pt) 1999-02-19 2000-02-08 Utilizacao de desoxipeganina no tratamento da demencia de alzheimer

Country Status (10)

Country Link
US (1) US6436937B1 (pt)
EP (1) EP1152762B8 (pt)
JP (1) JP2002537256A (pt)
KR (1) KR20010102219A (pt)
AT (1) ATE294584T1 (pt)
AU (1) AU2907700A (pt)
DE (2) DE19906975B4 (pt)
ES (1) ES2242605T3 (pt)
PT (1) PT1152762E (pt)
WO (1) WO2000048599A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19906978B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Pharmazeutische Zusammensetzung enthaltend Desoxypeganin zur Behandlung der Drogenabhängigkeit
DE19906979B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Verwendung von Desoxypeganin zur Behandlung der Nikotinabhängigkeit
EP1315495A2 (en) * 2000-08-28 2003-06-04 Sention, Inc. Use of threo-methylphenidate compounds to enhance memory
WO2002017920A2 (en) * 2000-08-28 2002-03-07 Sention, Inc Use of methylphenidate compounds to enhance memory
DE10119863A1 (de) * 2001-04-24 2002-11-07 Hf Arzneimittelforsch Gmbh Verwendung von Desoxypeganin zur Behandlung von psychiatrischen oder zerebralen Krankheitserscheinungen
DE10163667B4 (de) * 2001-12-21 2006-10-26 Hf Arzneimittelforschung Gmbh Verwendung von Desoxypeganin zur Behandlung der klinischen Depression
CA2460051A1 (en) * 2002-07-09 2004-01-15 Actelion Pharmaceuticals Ltd. 7,8,9,10-tetrahydro-6h-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2h-pyrrolo[2,1-b]-quinazolinone derivatives
DE10304141B4 (de) 2003-02-03 2006-03-09 Hf Arzneimittelforschung Gmbh Verfahren zur Herstellung von Chinazolin-Alkaloiden
DE10354893B4 (de) * 2003-11-24 2011-03-10 Hf Arzneimittelforschung Gmbh Verwendung von Desoxypeganin zur Behandlung schizophrener Psychosen
CN101433565B (zh) * 2008-11-26 2013-06-05 上海中医药大学 骆驼蓬属种子总生物碱提取物和它们的制备

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU605614A1 (ru) * 1971-10-20 1978-05-05 Ордена Трудового Красного Знамени Институт Химии Растительных Веществ Ан Узбекской Сср Антихолинэстеразное средство
SU878295A1 (ru) * 1979-07-04 1981-11-07 Ордена Трудового Красного Знамени Институт Химии Растительных Веществ Ан Узсср Способ получени дезоксипеганина гидрохлорида
US5750542A (en) * 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
SE9504618D0 (sv) 1995-12-22 1995-12-22 Astra Ab New Compounds

Also Published As

Publication number Publication date
KR20010102219A (ko) 2001-11-15
EP1152762B1 (de) 2005-05-04
DE19906975A1 (de) 2000-08-24
JP2002537256A (ja) 2002-11-05
ES2242605T3 (es) 2005-11-16
ATE294584T1 (de) 2005-05-15
DE50010234D1 (de) 2005-06-09
WO2000048599A1 (de) 2000-08-24
US6436937B1 (en) 2002-08-20
DE19906975B4 (de) 2004-04-15
EP1152762A1 (de) 2001-11-14
AU2907700A (en) 2000-09-04
EP1152762B8 (de) 2005-06-29

Similar Documents

Publication Publication Date Title
NO20022531D0 (no) Vaksine for forebyggelse og behandling av Alzheimer og amyloidrelaterte sykdommer
EP0735870A4 (en) USE OF PHOSPHOLIPASE-A2 INHIBITORS FOR TREATING ALZHEIMER'S DISEASE
GB0005251D0 (en) Therapeutic compounds
HK1087398A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
EP1767197A3 (en) Treatment of Alzheimer's disease with inhibitors of cell cycle re-entry and progression
ATE455106T1 (de) Acyl derivate zur behandlung von krankheiten die in zusammenhang mit vla-4 stehen
ATE385794T1 (de) Benzothiazolderivate zur behandlung von alzheimer und parkinson
AU2003284968A8 (en) Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease
HK1050860A1 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
UA41355C2 (uk) Засіб для лікування нейро-сніду
AU2002335794A1 (en) Allylamides useful in the treatment of alzheimer's disease
PT1152762E (pt) Utilizacao de desoxipeganina no tratamento da demencia de alzheimer
PT1007040E (pt) Utilizacao de fanquinona no tratamento da doenca de alzheimer
DE69420229D1 (de) Pharmazeutische Zusammensetzung zur Behandlung von AIDS
MX9707642A (es) Uso de 2-oxoindol-1-carboxamidas 3-sustituidas y sus sales de base farmaceuticamente aceptables para preparar composiciones para el tratamiento y prevencion de la enfermedad de alzheimer en mamiferos, incluyendo a humanos.
PT932400E (pt) Derivados de anticonvulsionantes uteis no tratamento da dor neuropatica
CA2260863A1 (en) Treatment of psychotic disorders
ATE236633T1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
DK0836853T3 (da) Anvendelse af bradykinin-antagonister til fremstilling af lægemidler til behandling og forebyggelse af Alzheimers sygdom
FI953725A0 (fi) Ornitiiniaminotransferaasi-inhibiittorien käyttö lääkeaineen valmistamiseksi Alzheimerin taudin hoitamiseksi
ES2127133A1 (es) Utilizacion de derivados 2,5-dihidroxibencenosulfonicos para la fabricacion de medicamentos destinados al tratamiento y a la prevencion de la enfermedad de alzheimer.
UA36252A (uk) Спосіб визначення індивідуальності хворого для вибору адекватної гомеопатичної терапії
EP1423144A4 (en) METHOD AND COMPOUNDS FOR INTERRUPTING THE CD40R / CD40L SIGNAL TRANSMISSION IN THE TREATMENT OF ALZHEIMER DISEASE
UA33498A (uk) Спосіб лікування терапевтично резистентних форм шизофренії
GB9910197D0 (en) Multivalent agents for use in the treatment of mitochondrial diseases